Apellis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APLS Nasdaq 2836 apellis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apellis Pharmaceuticals, Inc.

Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Mar 10th, 2026 6:01 am
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - Mar 3rd, 2026 2:30 am
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Mar 2nd, 2026 5:00 am
Assessing Apellis Pharmaceuticals (APLS) Valuation After Prolonged Share Price Weakness - Feb 26th, 2026 8:10 am
Apellis price target lowered to $18 from $20 at Wedbush - Feb 26th, 2026 6:36 am
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Feb 25th, 2026 6:55 am
Apellis (APLS) Q4 2025 Earnings Call Transcript - Feb 24th, 2026 10:41 pm
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Feb 24th, 2026 2:31 pm
Apellis Pharmaceuticals Inc (APLS) Q4 2025 Earnings Call Highlights: Strong EMPAVELI Launch and ... - Feb 24th, 2026 2:02 pm
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates - Feb 24th, 2026 9:00 am
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Feb 24th, 2026 9:00 am
Apellis Pharmaceuticals Q4 Earnings Call Highlights - Feb 24th, 2026 8:44 am
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Feb 24th, 2026 5:05 am
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - Feb 23rd, 2026 5:00 am
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting - Feb 19th, 2026 5:00 am
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline - Feb 18th, 2026 8:00 am
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline - Feb 17th, 2026 8:00 am
Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Feb 11th, 2026 9:11 am
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - Feb 10th, 2026 5:00 am
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Jan 29th, 2026 10:24 pm